HAEMATO AG | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
3,315.70
2,423.70
2,449.20
14,060.60
12,461.40
4.49
Total Accounts Receivable
7,947.50
12,031.00
5,015.30
6,958.90
11,606.80
10,251.20
Inventories
30,786.00
34,187.60
41,677.20
37,892.80
43,114.40
44,376.90
Other Current Assets
11,421.00
2,917.00
3,718.60
519.10
166.90
456.90
Total Current Assets
53,470.20
51,559.40
52,860.20
59,431.30
67,349.50
60,684.40
Net Property, Plant & Equipment
453.50
1,177.90
1,307.40
1,178.50
1,106.40
1,046.80
Total Investments and Advances
2,236.70
7,480.40
12,474.10
16,768.90
14,495.80
15,972.70
Intangible Assets
42,585.20
41,354.00
40,212.80
39,259.50
38,941.30
38,677
Other Assets
110.90
129.70
134.20
135.50
135.50
135.50
Total Assets
98,856.40
101,701.40
106,988.80
116,773.70
122,028.40
116,516.40
ST Debt & Current Portion LT Debt
12,542.50
13,027.70
22,175.10
2,724.40
7,821.40
Accounts Payable
6,659.70
7,244.10
5,683.90
6,410.30
7,522.10
Income Tax Payable
126.00
80.00
-
1.00
-
Other Current Liabilities
2,822.40
5,311.00
7,728.80
19,573.50
16,226.10
Total Current Liabilities
22,150.60
25,662.70
35,587.80
28,709.20
31,569.60
Long-Term Debt
17,059.30
15,959.30
12,190.00
24,209.30
19,000.00
Provision for Risks & Charges
78.60
20.90
20.90
13.40
13.30
Deferred Taxes
1,330.10
1,075.70
901.50
750.10
518.20
Total Liabilities
40,618.50
42,718.70
48,700.20
53,682.00
51,101.20
Common Equity (Total)
58,237.90
58,982.70
58,288.60
63,091.60
70,927.20
Total Shareholders' Equity
58,237.90
58,982.70
58,288.60
63,091.60
70,927.20
Total Equity
58,237.90
58,982.70
58,288.60
63,091.60
70,927.20
Liabilities & Shareholders' Equity
98,856.40
101,701.40
106,988.80
116,773.70
122,028.40

About HAEMATO

View Profile
Address
Lilienthalstraße 5c
Schönefeld Brandenburg 12529
Germany
Employees -
Website http://haemato.de
Updated 07/08/2019
Haemato AG engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes therapies for cancer, HIV, rheumatology, and other chronic diseases. It also consists of products for the privately financed market for aesthetic treatments.